December 8, 2016, Seoul – Institut Pasteur Korea (IPK) announced today that it is co-organizing and hosting a symposium entitled ‘French Health Care Day – Managing public health challenges in France and Korea’ on December 9th, in celebration of France-Korea Year 2015-2016. Co-organized by the French Embassy and the French Medical Alliance in Korea (FMAIK), this symposium will gather various stakeholders, public officials, and healthcare professionals from both countries to address the challenge raised by key global diseases such as cancer, tuberculosis and antibacterial resistance.
Mr. Fabien Penone, Ambassador of France in Korea, will open the symposium. During the first session, expert presentations on Infection Control for Multi Drug-Resistant Organisms (MDROs) in healthcare facilities and communities will address ways to reduce the impact and limit the spread of antibiotic resistance, an emerging global concern. This MDRO session will cover current status of resistant bacteria, surveillance programs and future countermeasures including ‘Global-PPS (The Global Point Prevalence Survey of Antimicrobial Consumption and Resistance), ‘GLASS (Global Antimicrobial Resistance Surveillance System) Korea’, and ‘One Health,’ a collaborative effort to attain optimal health for people, animals and the environment. Medical Affairs Director Marie-Francoise Gros from Biomerieux will commence the session with her presentation, which will be followed by those of Prof. Seok Hoon Jeong from Yonsei University, Deputy Scientific Director Kwang Jun Lee from Korean Centers for Disease Control (KCDC), and Dr. Soojin Jang from IPK.
In the second session entitled ‘Management of Hepatocellular carcinoma (HCC); Current Status and Future Perspectives’, an in-depth look will take place about HCC, the most common type of liver cancer, with its current methods of treatment as well as the paradigm changes in surgical treatment of the disease. The session will be including presentations from Dr. Haengran Seo from IPK, Prof. Yves Menu from Saint-Antoine Hospital, Prof. Kwang-Hyub Han from Yonsei University, and Prof. Kyung-Suk Suh from Seoul National University. During the session, the progressive practices in HCC management, from prediction and prevention among patients with high risk level to various methods of treatments, will be discussed and how imaging can be utilized to follow up patient recovery after treatment.
The last session, entitled ‘French-Korea Health Alliances for Tuberculosis (TB) Free’, will seek for the cooperative solutions to cure tuberculosis, for which Korea has the highest incidence and mortality rate of among all OECD countries. Experts including the Head of Tuberculosis Research Laboratory (TRL) Vincent Delorme from IPK, Vice president of Access to Medicine Robert Sebbag from Sanofi, Director of Division of HIV/AIDS and TB control OK Park from KCDC, and Planning Director of Private-Public Mix (PPM) Jae Seuk Park from Dankook University Hospital will be delivering their views on the disease – from new drug discovery based on the understanding of disease mechanism, and the present and future of tuberculosis screening and treatment to strategies and policies of the Korean government and French-Korean public private partnership in the related matter.
Mr. Fabien Penone, Ambassador of France in Korea, said, “A series of meaningful events have taken place to celebrate the 130thanniversary of diplomatic relations between France and Korea. I hope that this symposium will serve as an opportunity to expand the understanding of public health challenges in both France and Korea, and will provide possible solutions for major healthcare issues in Korea.” Mr. Penone added, “France is a leader in life sciences and drug research. We are glad to support this first French Health Care Day and we welcome this fruitful cooperation between IPK and the newly-created FMAIK. French companies will definitively continue to work together and share knowledge with Korean experts on major healthcare issues. The emerging partnership between French and Korean companies will lead to innovative solutions, sharing of best practices, and development of new products.”
Roberto Bruzzone, IPK CEO said, “We are honored to host a distinguished panel of French and Korean scientists, clinicians, and government officials for the French Health Care Day symposium,” adding, “For over a century, the special relationship between France and Korea has been extremely beneficial to both countries. As a culmination of the yearlong France-Korea Year celebration, this symposium will serve as a forum to address key healthcare issues of global concern with the aim to advance solutions, reduce knowledge gaps and meet patient’s needs.”
Mathieu Elie, Asia Pacific Director of Guerbet and Secretary General of French Medical Alliance in Korea (FMAIK) said, “As an innovation hub and one of the most advanced countries in terms of medical innovation, South Korea is a very important place for French companies, especially in the areas of medical imaging, biosimilars, and medical equipment,” adding, “In order to draw a strong capacity for innovation, it is important for the government, enterprises, academia and think tanks and hospitals to be closely connected. The French Medical Alliance in Korea will provide full support for French companies to expand and find more cooperation opportunities in Korea.”
The France-Korea Year 2015-2016 was established to celebrate 130 years of bilateral diplomatic relationship between France and Korea, and various events in the fields of culture, education, IT, and economy, have been organized Korea from March to December 2016, in Seoul and Korea’s other main cities. From September 2015 to August 2016, more than 2.2 million French nationals have experienced the Korean culture via 200 events held in France and events introducing the French culture were also held in Korea since January of this year.
About Institut Pasteur Korea
Institut Pasteur Korea (IPK) is an international research institute focused on addressing global health issues with a combination of cutting edge approaches in order to understand disease mechanisms and develop new treatments. By promoting multi-disciplinary projects, IPK is at the forefront of drug discovery and an economic growth engine that contributes to Korea’s scientific intellectual and technical resources. IPK has four core missions of public interest – 1) Research, combining front line biology, IT, and chemistry, with innovative cell-based drug discovery platforms that identify novel molecular targets for potential new therapies to treat diseases, 2) Education, offering a wide range of programming to nurture the development of the next generation of scientists and health professionals, 4) Public Health, working in collaboration with national and international health authorities, and 4) Translation of biomedical discoveries to improve health via technology transfer and industrial partnerships.
IPK is a member of the Institut Pasteur International Network (Network). As a hub institution, IPK plays a key role in the Network, serving as a bridge between Korea and global bio-pharma science, expanding Korea’s R&D base collaborative research projects with global alliances
The institute was established in April 2004 in collaboration with Institut Pasteur Paris and the Korea Institute of Science and Technology (KIST), with support from the Ministry of Science, ICT and Future Planning (MSIP). IPK also has a great supporter in the Gyeonggi Provincial government (2005 – 2015 : Block funding | 2016 – Present : drug discovery co-research fund for pharm industries).
For more information on Institut Pasteur Korea, visit us at http://www.ip-korea.org/.